FVFleur Vansenne

Fleur Vansenne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fleur Vansenne has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pathogenic variants in the autophagy-tethering factor EPG5 drive neurodegeneration through mitochondrial dysfunction and innate immune activation

    by Kritarth Singh, Hormos Salimi Dafsari, Olivia Gillham, Haoyu Chi, Ivet Mandzhukova, Ioanna Kourouzidou, Preethi Sheshadri, Chih-Yao Chung, Valeria Pingitore, Fleur Vansenne, et al.

    The autophagy-tethering factor ectopic P-granule 5 autophagy protein (EPG5) plays a key role in autophagosome-lysosome fusion. Impaired autophagy associated with pathogenic variants in EPG5 causes a rare devastating multisystem disorder known as Vici syndrome, which features neurodevelopmental defects, severe progressive neurodegeneration and immunodeficiency. The pathophysiological mechanisms driving disease presentation and progression are only partially understood. In patient-derived fibroblasts and iPS cells differentiated to cortical neurons, we find that impaired mitophagy leads to mitochondrial bioenergetic dysfunction. Physiological cytosolic Ca 2+ transients result in unexpected mitochondrial Ca 2+ overload despite a decrease in mitochondrial membrane potential. This is attributed to downregulation of MICU1. Ca 2+ signals cause mitochondrial depolarisation, mtDNA release and activation of the cGAS-STING pathway, reversed by pharmacological inhibition of the mitochondrial permeability transition pore (mPTP) or of the STING pathway. Thus, we identify a pathophysiological cascade driving disease progression associated with EPG5 deficiency, including impaired mitochondrial bioenergetics, mitochondrial Ca 2+ overload, vulnerability to mPTP opening and activation of innate immune signalling, signposting multiple potential therapeutic targets.


  • Open Access

    Pathogenic variants in autophagy-tethering factor EPG5 drive neurodegeneration through mitochondrial dysfunction and innate immune activation

    by Kritarth Singh, Hormos Salimi Dafsari, Olivia Gillham, Haoyu Chi, Ivet Mandzhukova, Ioanna Kourouzidou, Preethi Sheshadri, Chih-Yao Chung, Valeria Pingitore, Fleur Vansenne, et al.

    The autophagy-tethering factor, ectopic P-granule 5 autophagy protein (EPG5), plays a key role in autophagosome-lysosome fusion. Impaired autophagy associated with pathogenic variants in EPG5 cause a rare devastating multisystem disorder known as Vici syndrome, which includes neurodevelopmental defects, severe progressive neurodegeneration and immunodeficiency. The pathophysiological mechanisms driving disease presentation and progression are not understood. In patient-derived fibroblasts and iPS cells differentiated to cortical neurons, we found that impaired mitophagy leads to mitochondrial bioenergetic dysfunction. Physiological Ca 2+ signals resulted in paradoxical mitochondrial Ca 2+ overload attributed to downregulation of MICU1/3. Ca 2+ signals caused mitochondrial depolarisation, mtDNA release and activation of the cGAS-STING pathway, reversed by pharmacological inhibition of the mitochondrial permeability transition pore (mPTP) or of the STING pathway. Thus, we have identified multiple potential therapeutic targets driving disease progression associated with pathogenic EPG5 mutations, including impaired mitochondrial bioenergetics, mitochondrial Ca 2+ overload, vulnerability to mPTP opening and activation of innate immune signalling.


  • Open Access

    High Prevalence of the Intronic GAA- FGF14 Repeat Expansion in Dutch Patients With Late-Onset Ataxia

    by Ana Ignjatijevic, Femke Boorsma, Elles Wierenga, Fleur Vansenne, Corien C. Verschuuren-Bemelmans, Jeroen de Vries, Dineke S. Verbeek, Helga Westers, Cleo C. van Diemen

    A pathogenic GAA repeat expansion in the first intron of the fibroblast growth factor 14 (FGF14) gene was recently identified as a common cause of late-onset spinocerebellar ataxia in various populations. In our hospital, approximately 85% of adult-onset ataxia cases remain genetically unsolved and the prevalence of the GAA-FGF14 repeat expansion is unknown. We, therefore, screened 248 Dutch individuals with adult-onset spinocerebellar ataxia for GAA-FGF14 repeat expansions using a combination of long-range PCR (LR-PCR) and repeat-primed PCR (RP-PCR) and assessed their clinical presentation. Genomic DNA samples from 248 genetically unsolved patients with adult-onset ataxia were first tested by LR-PCR spanning the intronic FGF14 repeat locus to detect expanded alleles. The correct repeat motif was verified by RP-PCR of the GAA and another prevalent repeat, GAAGGA. GAA-positive repeats were accurately sized with fluorescent LR-PCR and fragment length analysis. Three samples were validated using Oxford Nanopore Technologies long-read sequencing. Clinical data of the patients with GAA≥250-FGF14 were collected retrospectively. The (likely) pathogenic GAA≥250-FGF14 repeat expansion was identified in 28 patients, resulting in a total diagnostic yield of 11%. These patients commonly presented with late-onset gait ataxia, vertigo, and nystagmus. Nine individuals had a GAAGGA expansion that is considered nonpathogenic. We conclude that GAA-FGF14 repeat expansions are one of the most common known genetic causes of late-onset spinocerebellar ataxia in patients referred to our hospital, which is comparable with studies in other populations. The inclusion of GAA-FGF14 genetic testing will significantly improve the diagnostic yield.


  • Open Access

    Pathogenetic Insights into Developmental Coordination Disorder Reveal Substantial Overlap with Movement Disorders

    by Martinica Garofalo, Fleur Vansenne, Deborah A. Sival, Dineke S. Verbeek

    Developmental Coordination Disorder (DCD) is a neurodevelopmental condition characterized by non-progressive central motor impairments. Mild movement disorder features have been observed in DCD. Until now, the etiology of DCD has been unclear. Recent studies suggested a genetic substrate in some patients with DCD, but comprehensive knowledge about associated genes and underlying pathogenetic mechanisms is still lacking. In this study, we first identified genes described in the literature in patients with a diagnosis of DCD according to the official diagnostic criteria. Second, we exposed the underlying pathogenetic mechanisms of DCD, by investigating tissue- and temporal gene expression patterns and brain-specific biological mechanisms. Third, we explored putative shared pathogenetic mechanisms between DCD and frequent movement disorders with a known genetic component, including ataxia, chorea, dystonia, and myoclonus. We identified 12 genes associated with DCD in the literature, which are ubiquitously expressed in the central nervous system throughout brain development. These genes are involved in cellular processes, neural signaling, and nervous system development. There was a remarkable overlap (62%) in pathogenetic mechanisms between DCD-associated genes and genes linked with movement disorders. Our findings suggest that some patients might have a genetic etiology of DCD, which could be considered part of a pathogenetic movement disorder spectrum.


  • Open Access

    Pathogenetic Insights in Developmental Coordination Disorder Reveal Substantial Overlap with Movement Disorders

    by Martinica Garofalo, Fleur Vansenne, Deborah A. Sival, Dineke S. Verbeek

    Developmental Coordination Disorder (DCD) is a neurodevelopmental condition characterized by non-progressive central motor impairments. Mild movement disorder features have been observed in DCD. Until now, the etiology of DCD remains unclear. Recent studies suggested a genetic substrate in some patients with DCD, but comprehensive knowledge about associated genes and underlying pathogenetic mechanisms is still lacking. In this study, we first identified genes described in literature in patients with a diagnosis of DCD according to the official diagnostic criteria. Second, we exposed the underlying pathogenetic mechanisms of DCD, by investigating tissue- and temporal gene expression patterns and brain-specific biological mech-anisms. Third, we explored putative shared pathogenetic mechanisms between DCD and frequent movement disorders with a known genetic component, including ataxia, chorea, dystonia, and myoclonus. We identified 12 genes associated with DCD in literature, which are ubiquitously expressed in the central nervous system throughout brain development. These genes are involved in cellular processes, neural signaling and nervous system development. There was a remarkable overlap (62%) in pathogenetic mechanisms between DCD-associated genes and genes linked with movement disorders. Our findings suggest that some patients might have a genetic etiology of DCD, which could be considered part of a pathogenetic movement disorder spectrum.


  • Pathogenic TRIO variants associated with neurodevelopmental disorders perturb the molecular regulation of TRIO and axon pathfinding in vivo

    by Maxime Bonnet, Fiona Roche, Christine Fagotto-Kaufmann, Gabriella Gazdagh, Iona Truong, Franck Comunale, Sonia Barbosa, Marion Bonhomme, Nicolas Nafati, David Hunt, et al.

    The RhoGEF TRIO is known to play a major role in neuronal development by controlling actin cytoskeleton remodeling, primarily through the activation of the RAC1 GTPase. Numerous de novo mutations in the TRIO gene have been identified in individuals with neurodevelopmental disorders (NDDs). We have previously established the first phenotype/genotype correlation in TRIO-associated diseases, with striking correlation between the clinical features of the individuals and the opposite modulation of RAC1 activity by TRIO variants targeting different domains. The mutations hyperactivating RAC1 are of particular interest, as they are recurrently found in patients and are associated with a severe form of NDD and macrocephaly, indicating their importance in the etiology of the disease. Yet, it remains unknown how these pathogenic TRIO variants disrupt TRIO activity at a molecular level and how they affect neurodevelopmental processes such as axon outgrowth or guidance. Here we report an additional cohort of individuals carrying a pathogenic TRIO variant that reinforces our initial phenotype/genotype correlation. More importantly, by performing conformation predictions coupled to biochemical validation, we propose a model whereby TRIO is inhibited by an intramolecular fold and NDD-associated variants relieve this inhibition, leading to RAC1 hyperactivation. Moreover, we show that in cultured primary neurons and in the zebrafish developmental model, these gain-of-function variants differentially affect axon outgrowth and branching in vitro and in vivo, as compared to loss-of-function TRIO variants. In summary, by combining clinical, molecular, cellular and in vivo data, we provide compelling new evidence for the pathogenicity of novel genetic variants targeting the TRIO gene in NDDs. We report a novel mechanism whereby the fine-tuned regulation of TRIO activity is critical for proper neuronal development and is disrupted by pathogenic mutations.


  • Open Access

    Phenotypic expansion of EGP5-related Vici syndrome: 15 Dutch patients carrying a founder variant

    by Fleur Vansenne, Johanna M. Fock, Irene Stolte-Dijkstra, Linda C. Meiners, Marie-Jose H. van Den Boogaard, Bregje Jaeger, Ludolf Boven, Yvonne J. Vos, Richard J. Sinke, Dineke S. Verbeek


  • Open Access

    How to detect late-onset inborn errors of metabolism in patients with movement disorders – A modern diagnostic approach

    by Lisette H. Koens, Jeroen J. de Vries, Fleur Vansenne, Tom J. de Koning, Marina A.J. Tijssen